Skip to main content
. 2020 Mar 9;122(8):1158–1165. doi: 10.1038/s41416-020-0769-y

Table 2.

The best overall response (FAS, dose-expansion part).

Parameters All patients
n = 35, n (%)
95% CI
Best overall response
 Complete response (CR) 0
 Partial response (PR) 0
 Stable disease (SD) 19 (54.3)
 Progressive disease (PD) 14 (40.0)
 Unknown 2 (5.7)
Clinical benefit rate (CBR): CR + PR + SD ≥ 16 weeks 10 (28.6) 14.6–46.3
Overall response rate (ORR): CR + PR 0 0–10.0
Disease control rate (DCR): CR + PR + SD 19 (54.3) 36.6–71.2

CI confidence interval, FAS full-analysis set.